NRx Pharmaceuticals (NRXP)
Develops NMDA-pathway CNS therapies alongside a majority-owned interventional-psychiatry clinic network.
$3.41
Pre-market−0.04 (−1.30%)
At close$3.46(+0.44%)
Something off on this page? Send us feedback.
Next report
Nov 13, 2026
in 71 days
EPS estimate
−$0.26
Revenue estimate
$1.3M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported−$0.30−$0.34−$0.18$0.19−$0.04−$0.44−$0.44Pending
Estimate−$0.20−$0.30−$0.11−$0.09−$0.05−$0.11−$0.11−$0.26
Surprise−50.0%−13.3%−63.6%+311.1%+20.0%−312.5%−312.5%—
RevenueReportedEstimate
Mar '25May '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported$4.0K$2.3M$242.0K$983.0K$1.1M$1.1M$1.1MPending
Estimate$5.0M—$7.5M$7.5M$19.4M$1.3M$1.3M$1.3M
Surprise−99.9%—−96.8%−86.9%−94.5%−17.2%−17.2%—
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.26 | — | — |
| Aug 2026 | −$0.11 | −$0.44 | −312.5% |
| Aug 2026 | −$0.11 | −$0.44 | −312.5% |
| May 2026 | −$0.05 | −$0.04 | +20.0% |
| Mar 2026 | −$0.09 | $0.19 | +311.1% |
The latest year is open to everyone — the 31 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Apr 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | −$0.26 | — | — | $1.3M | — | — | — |
| Aug 17, 2026 | −$0.11 | −$0.44 | −312.5% | $1.3M | $1.1M | −17.2% | +4.9% |
| Aug 14, 2026 | −$0.11 | −$0.44 | −312.5% | $1.3M | $1.1M | −17.2% | +4.9% |
| May 15, 2026 | −$0.05 | −$0.04 | +20.0% | $19.4M | $1.1M | −94.5% | −4.9% |
| Mar 23, 2026 | −$0.09 | $0.19 | +311.1% | $7.5M | $983.0K | −86.9% | +20.3% |
The latest year is open to everyone — the 31 quarters behind it read with an account. Sign in | |||||||
| Nov 14, 2025 | |||||||
| May 15, 2025 | |||||||
| Mar 14, 2025 | |||||||
| Nov 14, 2024 | |||||||
| Aug 14, 2024 | |||||||
| May 14, 2024 | |||||||
| Mar 29, 2024 | |||||||
| Nov 13, 2023 | |||||||
| Aug 14, 2023 | |||||||
| May 16, 2023 | |||||||
| Mar 30, 2023 | |||||||
| Nov 14, 2022 | |||||||
| Aug 15, 2022 | |||||||
| May 16, 2022 | |||||||
| Mar 31, 2022 | |||||||
| Nov 16, 2021 | |||||||
| Aug 16, 2021 | |||||||
| May 20, 2021 | |||||||
| Apr 1, 2021 | |||||||
| Nov 16, 2020 | |||||||
| Aug 14, 2020 | |||||||
| May 15, 2020 | |||||||
| Mar 30, 2020 | |||||||
| Nov 14, 2019 | |||||||
| Aug 14, 2019 | |||||||
| May 15, 2019 | |||||||
| Mar 15, 2019 | |||||||
| Nov 8, 2018 | |||||||
| Aug 8, 2018 | |||||||
| May 15, 2018 | |||||||
| Mar 23, 2018 | |||||||